HBV-TCR T cell therapy: Preclinical and clinical insights into specificity, safety and efficacy for treating HBV-related HCC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...
With a closer look at genomic variation, scientists now have a faster, more precise way to uncover new links to disease EMBL ...
Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL). The therapy was ...
However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback